C4 Therapeutics shareholders approve doubling authorized common shares to 300M at annual meeting

C4 Therapeutics, Inc.

Shareholders elected Ronald Cooper, Donna Grogan, and Steven Hoerter as Class II directors for terms expiring 2028.
Non-binding advisory vote on executive compensation passed with 48.85M for vs 0.89M against.
Ratification of KPMG as auditor for FY2025 approved with 60.18M for, 0.08M against.
Amendment to increase authorized common shares from 150M to 300M approved with 39.55M for, 20.66M against.
Certificate of Amendment filed and effective June 18, 2025.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.